Companies
Autobio Diagnostics
a major domestic in-vitro diagnostics company, participates in China's antibiotic-susceptibility and broader IVD testing market.
- Country
- China
- Ticker
- SZSE:603658
Commercial
Domestic AST/IVD platforms
Coverage
| CN | EU | US | |
|---|---|---|---|
| analytics-pat | ✓ | ✓ | ✓ |
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | 1998 | medbot.cn |
| Headquarters | Zhengzhou, China | en.autobio.com.cn |
| Production site | Autobio industrial park in Zhengzhou, Henan Province, featuring over 720,000 square meters of facilities. | medbot.cn |
| Capacity | Upon completion of the industrial park, the company will have over US$ 2.2 billion in production capacity. medium confidence | en.autobio.com.cn |
| Certification | Holds over 326 IVDR CE certificates; certified under GMP, ISO9001, and ISO13485. | en.autobio.com.cn · medbot.cn |
| Regulatory approval | Holds over 850 product registration certificates; specific products like the Autof ms1000 have FDA clearance; medical device manufacturing license renewed as of July 2026. | medbot.cn · marketscreener.com |
| Headcount | 5,700 to 6,000+ employees | en.autobio.com.cn · marketscreener.com |
| Revenue | CNY 4.47 billion for 2024 | en.autobio.com.cn · medbot.cn · reuters.com |
Independent sources: en.autobio.com.cn · marketscreener.com · medbot.cn · reuters.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Automated ELISA analyzers | analytics-pat | Low | → |
| Rapid antibiotic-resistance tests | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.